SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1) /1/
AtheroGenics, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.001 per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
047439104
------------------------------
(CUSIP Number)
December 31, 2000
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|_| Rule 13d-1(c)
|X| Rule 13d-1(d)
----------
/1/ The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. 047439104 13G Page 2 of 8
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
William Blair Capital Partners VI, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
--------------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 2,678,667 (See Item 4) Includes options to buy 12,000
OWNED BY shares at an exercise price of $0.38 per share.
EACH --------------------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON
WITH 0
--------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
2,678,667 (See Item 4) Includes options to buy 12,000
shares at an exercise price of $0.38 per share.
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,678,667 (See Item 4) Includes options to buy 12,000 shares at an exercise
price of $0.38 per share.
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
|_|
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11.2%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
CUSIP No. 047439104 13G Page 2 of 8
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
William Blair Capital Partners VI, L.L.C.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
0
--------------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY 2,678,667 (See Item 4) Includes options to buy 12,000
OWNED BY shares at an exercise price of $0.38 per share.
EACH --------------------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON
WITH 0
--------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
2,678,667 (See Item 4) Includes options to buy 12,000
shares at an exercise price of $0.38 per share.
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,678,667 (See Item 4) Includes options to buy 12,000 shares at an exercise
price of $0.38 per share.
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
|_|
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11.2%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
OO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
SCHEDULE 13G
Item 1(a). Name of Issuer:
AtheroGenics, Inc. (the "Company")
Item 1(b). Address of Issuer's Principal Executive Offices:
8995 Westside Parkway
Alpharetta, GA 30004
Item 2(a). Name of Persons Filing:
This statement is filed jointly by each of the following Persons
pursuant to Rule 13d-1(k) promulgated by the Securities and Exchange
Commission ("SEC") under Section 13 of the Securities Exchange Act
of 1934, as amended (the "Act"): (i) William Blair Capital Partners
VI, L.P., a Delaware limited partnership (the "Fund"), by virtue of
its direct beneficial ownership of Common Stock and (ii) William
Blair Capital Partners VI, L.L.C. ("WBCPCO," together with the Fund,
each a "Reporting Person" and collectively, "Reporting Persons"), a
Delaware limited liability company, by virtue of its being the
general partner of the Fund. By virtue of being members of the Board
of Managers of WBCPCO (the "Board"), E. David Coolidge, III, John P.
Kayser, Robert D. Blank, Ellen Carnahan, David G. Chandler, James M.
Denny, Edgar D. Jannotta, Ian M. Larkin, Arda Minocherhomjee,
Timothy M. Murray, Greggs S. Newmark, Lawrence I. Shagrin and Thomas
C. Theobald may be deemed to possess indirect beneficial ownership
of the Common Stock, but such beneficial ownership is disclaimed.
Only the Board, acting upon the consent of a majority of the members
of the Board at any meeting of the Board where a quorum is present,
possesses the right to vote, direct the vote, dispose or direct the
disposition of the Common Stock. No individual has sole power to
vote, direct the vote, dispose or direct the disposition of the
Common Stock. The Reporting Persons have entered into an Agreement
Related to the Joint Filing of Schedule 13G, dated February 14,
2000, a copy of which is filed with this Schedule 13G as Exhibit A,
pursuant to which the Reporting Persons have agreed to file this
statement jointly in accordance with the provisions of Rule 13d-1(k)
under the Act. Information with respect to each of the Reporting
Persons is given solely by such Reporting Person, and no Reporting
Person assumes responsibility for the accuracy or completeness of
information provided by another Reporting Person. By their signature
on this statement, each of the
Page 4 of 8
Reporting Persons agrees that this statement is filed on behalf of
such Reporting Person. The Reporting Persons may be deemed to
constitute a "group" for purposes of Section 13(d)(3) of the Act.
The Reporting Persons expressly disclaim that they have agreed to
act as a group other than as described in this statement.
Item 2(b). Address of Principal Business Office or, if none, Residence:
The address of the principal business office of each of the
Reporting Persons is 222 West Adams Street, Chicago, Illinois 60606.
Item 2(c). Citizenship:
The Fund is a Delaware limited partnership and WBCPCO is a Delaware
limited liability company.
Item 2(d). Title of Class of Securities:
Common Stock, par value $0.001 per share ("Common Stock").
Item 2(e). CUSIP No.:
047439104
Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or
(c), check whether the person filing is a:
Not Applicable.
Item 4. Ownership (as of December 31, 2000):
As of December 31, 2000, the Fund was the registered owner Of
2,678,667 shares of Common Stock or approximately 11.2% of the total
number of shares of Common Stock outstanding as of such date (based
upon information provided by the Company) which includes options to
buy 12,000 shares at an exercise price of $0.38 per share. By virtue
of the relationship between the Fund and WBCPCO described in Item
2(a), WBCPCO may be deemed to possess indirect beneficial ownership
of and shares the power to vote or direct the vote of the shares of
Common Stock beneficially owned by the Fund. WBCPCO disclaims
beneficial ownership of the shares of Common Stock owned by the
Fund. The filing of this statement by WBCPCO shall not be construed
as an admission that they are, for the purpose of Section 13(d) or
Section 13(g) of the Act, the beneficial owner of any securities
covered by this statement.
Page 5 of 8
Item 5. Ownership of Five Percent or Less of a Class:
Not Applicable.
Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company:
Not Applicable.
Item 8. Identification and Classification of Members of the Group:
Not Applicable.
Item 9. Notice of Dissolution of a Group:
Not Applicable.
Item 10. Certification:
Not Applicable.
Page 6 of 8
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.
Date: February 14, 2001
William Blair Capital Partners
VI, L.P.
By: William Blair Capital
Partners VI, L.L.C., its
general partner
By: /s/ Gregg S. Newmark
-------------------------------------
Its: Senior Managing Director
William Blair Capital Partners
VI, L.L.C.
By: /s/ Gregg S. Newmark
-------------------------------------
Its: Senior Manging Director
Page 7 of 8
EXHIBIT A
AGREEMENT REGARDING THE JOINT FILING OF
SCHEDULE 13G
----------
William Blair Capital Partners VI, L.P. and William Blair Capital Partners VI,
L.L.C. hereby agree that the Statement on Schedule 13G to which this agreement
is attached as an exhibit, as well as all future amendments to such Statement,
shall be filed jointly on behalf of each of them. This agreement is intended to
satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange
Act of 1934, as amended.
Date: February 14, 2001
William Blair Capital Partners
VI, L.P.
By: William Blair Capital
Partners VI, L.L.C., its
general partner
By: /s/ Gregg S. Newmark
-------------------------------------
Its:
-----------------------------------
William Blair Capital Partners
VI, L.L.C.
By: /s/ Gregg S. Newmark
-------------------------------------
Its:
-----------------------------------
Page 8 of 8